BRAF and melanoma: Consistently with previous data from Altieri's group showing that BRAF-mutated melanoma cells exhibit increased sensitivity to gamitrinib-induced cell death, compared to wild type BRAF melanoma cells [17], CRC cell lines and drug-resistant CRC cells showed high sensitivity to subcytotoxic concentrations of gamitrinib with higher apoptotic rates and impaired colony and foci formation.